Lilly Inks R&D Deal With Indian Firm Potentially Worth $100 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Indianapolis drug maker says that potential compounds could address therapeutic areas outside company's focus.
You may also be interested in...
Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
Eli Lilly is gaining a portfolio of molecules targeting the vanilloid-1 receptor, including Phase II candidate GRC 6211, through an agreement with Mumbai, India-based Glenmark Pharmaceuticals, announced Oct. 30
Bristol Expands R&D In India Through Biocon Deal
Bristol-Myers Squibb is expanding its research and development presence in India through a deal with Bangalore-based Biocon on discovery research work involving medicinal chemistry, biology and drug metabolism, the firms announced March 14
Bristol Expands R&D In India Through Biocon Deal
Bristol could open more R&D centers in India as part of the agreement, firm tells “The Pink Sheet” DAILY.